Indivumed GmbH is a physician-led, integrated global oncology company with the world's premier high-content tumor database and highest quality biobank. The company was founded in 2002 by leading scientists to establish what is now considered the most advanced approach to biospecimen and clinical data collection, preservation, and analysis. We are headquartered in Hamburg, Germany, with a US-based subsidiary and a global clinical network.
Indivumed has established a comprehensive molecular platform for drug profiling to perform mode of action studies in patient-derived, intact tumor tissues, and to predict the efficacy and absorption of drug compounds in a preclinical setting. These models improve understanding of drug effects in heterogeneous patient populations and help to design and predict the outcome of clinical trials.
Customers can choose between primary human tumor cells and intact tumor tissue.
Primary cells are particularly useful for the study of surface molecules and studies on a single-cell level. They can also be used to determine possible drug effects on cellular proliferation and evaluate potential toxic effects on normal cells.
The intact tissue model is based on the short-term cultivation of floating 200-400 µm slices of intact tumor tissue. With the exception of single-cell analysis of surface molecules, all assays applicable for primary cells can be used. A major advantage of using tumor tissue is the analysis of cancer cells within the tumor environment. Customers will receive a clinical report including analyses of the results, a pathological assessment, and clinical information about the tissue donors.
Indivumed's drug profiling platform allows, among other services, testing and confirmation of drug effects in a natural tumor environment, prioritization of compounds before entry into clinical trials, and profiling of drug candidates in different tumor entities.
Indivumed provides high-quality immunohistochemistry (IHC) services embedded in an ISO-certified company and a GCLP-compliant environment. This includes prevalence studies, validation of biomarkers, targets, or antibodies; with either Indivumed's own tissue samples, biospecimen from Indivumed-qualified external resources using a “pathoscoring system” (real-world tissue), or samples provided by customers.
Based on the Ventana® Discovery and Benchmark Technology, Indivumed has established automated staining protocols for numerous proteins in FFPE specimens, as well as frozen tissue with a special emphasis on phosphoproteins. Customized IHC protocol development with commercially available antibodies or research antibodies can be performed according to a customer’s specialized needs.
Additionally, customers receive a comprehensive report package including (but not limited to) high-quality digital images and an interpretation of the staining patterns by experienced staff pathologists. Quantification of staining results by automated image analysis and verification of results by a pathologist are available on request.
Human Biospecimen Management and Storage Services
Protein Expression Visualization Services
Biochemistry & Molecular Biology Services
Indivumed GmbH has not received any reviews.
Indivumed GmbH has not received any endorsements.